Stoke Therapeutics (NASDAQ:STOK) Now Covered by Chardan Capital

Stock analysts at Chardan Capital began coverage on shares of Stoke Therapeutics (NASDAQ:STOK - Get Free Report) in a note issued to investors on Friday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $24.00 price target on the stock. Chardan Capital's price target suggests a potential upside of 105.48% from the stock's current price.

Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Leerink Partners assumed coverage on Stoke Therapeutics in a report on Monday, October 14th. They issued an "outperform" rating and a $18.00 target price for the company. Leerink Partnrs upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Friday, October 11th. Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $21.29.

Stoke Therapeutics Trading Up 3.4 %

STOK traded up $0.38 during mid-day trading on Friday, hitting $11.68. 1,156,170 shares of the stock were exchanged, compared to its average volume of 744,608. The firm's fifty day moving average is $12.49 and its two-hundred day moving average is $13.58. Stoke Therapeutics has a 1-year low of $4.09 and a 1-year high of $17.58. The company has a market cap of $618.65 million, a PE ratio of -5.56 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $4.89 million for the quarter, compared to analysts' expectations of $3.46 million. As a group, research analysts anticipate that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insider Activity at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 9,696 shares of the business's stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $12.78, for a total value of $123,914.88. Following the transaction, the general counsel now owns 35,142 shares of the company's stock, valued at approximately $449,114.76. The trade was a 21.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the company's stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the transaction, the insider now owns 51,277 shares of the company's stock, valued at approximately $618,913.39. The trade was a 16.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 62,849 shares of company stock valued at $809,421 in the last three months. 11.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC purchased a new position in Stoke Therapeutics in the second quarter worth $29,000. Nisa Investment Advisors LLC increased its holdings in shares of Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company's stock valued at $40,000 after purchasing an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Stoke Therapeutics in the second quarter valued at about $123,000. Intech Investment Management LLC purchased a new stake in Stoke Therapeutics during the third quarter worth about $160,000. Finally, The Manufacturers Life Insurance Company grew its position in Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock worth $189,000 after buying an additional 1,994 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.